Date: 2011-05-17
Type of information: Distribution agreement
Compound: ImmuCyst®
Company: Alliance Pharma (UK) Sanofi Pasteur (France)
Therapeutic area: Cancer- Oncology
Type agreement: distribution
Action mechanism:
Disease: non-muscle-invasive bladder cancer
Details: Alliance Pharma has announced the renewal for a period of up to seven years of its agreement with sanofi pasteur, the vaccines division of Sanofi, for the distribution of ImmuCyst® in the UK and Ireland. Sales of the product in the twelve months ended 30 April 2011 in the UK and Ireland were £3.7 million (€ 4.22 million). ImmuCyst® has been distributed by Alliance's Cambridge Laboratories business unit since the acquisition of the trade and certain assets of Cambridge Laboratories in February 2010.
Financial terms: The renewal of the ImmuCyst® distribution agreement triggers the payment by Alliance of up to £2.1 million (€ 2.39 million) deferred cash consideration for Cambridge Laboratories.
Latest news:
